Biotherus Inc. Advances PM8002 Bispecific Antibody to Phase III for Triple Negative Breast Cancer
China’s Biotheus Inc. has announced the initiation of a Phase III clinical study for its...
Jiangsu Hengrui’s Camrelizumab/Apatinib Combo Denied FDA Approval Over Manufacturing Issues
The US Food and Drug Administration (FDA) has issued a complete response letter to Jiangsu...
ImmuneOnco Biopharmaceuticals’ CD47 Inhibitor Receives NMPA Go-Ahead for Phase III Trial
ImmuneOnco Biopharmaceuticals (Shanghai) Co., Ltd has announced that it has received approval from the National...
Siemens Healthineers and Ruijin Hospital Collaborate to Build Medical Digital Human Metaverse
Siemens Healthineers AG, the German medical technology major, has entered into a strategic partnership with...
CSPC Pharmaceutical’s βKlotho Monoclonal Antibody JMT202 Receives Clinical Trial Approval from NMPA
CSPC Pharmaceutical Group Ltd (HKG: 1093), a leading pharmaceutical company based in China, has announced...
Roche’s CT-388 Shows Significant Weight Loss in Phase I Clinical Trial for Obesity
Switzerland-based healthcare giant Roche (SWX: ROG) has announced preliminary results from a Phase I study...
Biocytogen Expands Reach to India with GVSAP Partnership for BioMice Models
A recent stock exchange announcement from China-based Biocytogen (HKG: 2315) has highlighted a strategic partnership...
HutchMed Chairman Simon To Steps Down, Dr. Dan Eldar Appointed Successor
HutchMed (NASDAQ: HCM, HKG: 0013) today announced a significant change in leadership with the long-serving...
Eisai to Support Grassroots Healthcare in China with Significant Pariet Donation
Eisai (TYO: 4523), a leading Japanese pharmaceutical company, has announced its commitment to donate 100,000...
North China Pharmaceutical’s Ormutivimab Approved for Pediatric Use in China
North China Pharmaceutical Group Corporation (SHA: 600812) has announced that it has received approval from...
HutchMed’s Sovleplenib Phase III Results to be Showcased at EHA 2024
HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013), a biopharmaceutical company based in China, is preparing...
Shanghai UniCAR-Therapy’s Innovative CAR-T Therapy Targets Breakthrough Designation with IL-6 Silencing
Shanghai UniCAR-Therapy Bio-Medicine Technology Co., Ltd, a leading biopharmaceutical company based in China, is on...
Sol-Gel Technologies Partners with Shenzhen Beimei for Twyneo Commercialization in China
Israel-based dermatology specialist Sol-Gel Technologies Ltd. (NASDAQ: SLGL) has announced the signing of a licensing...
J&J Acquires Immune-Mediated Diseases Specialist Proteologix in a Deal Worth Up to USD 850 Million
Johnson & Johnson (J&J; NYSE: JNJ), a global healthcare giant, has announced a deal to...
China’s Health Commission Boosts Efforts to Monitor and Respond to Drug Shortages
The National Health Commission (NHC) of China has recently announced the reinforcement of national and...
Huaixi Medical and Beijing HumaDX Tech Join Forces to Boost In Vitro Diagnostics
Huaixi Medical, a Nanjing-based specialist in flow cytometry, has entered into a strategic partnership with...
Bayer’s 225Ac-PSMA-Trillium Therapy Begins Early-Stage Clinical Trial for mCRPC
Bayer AG (ETR: BAYN), a multinational pharmaceutical company based in Germany, has this week commenced...
Merck KGaA Subsidiary Teams Up with Aulos Bioscience to Test PD-L1 and Anti-IL-2 Combination
Germany’s Merck KGaA (ETR: MRK) has announced that its Switzerland-based subsidiary, Ares Trading, has entered...
Chunlizhengda’s Handheld Orthopedic Robot Approved by China’s NMPA
Beijing Chunlizhengda Medical Instruments Co., Ltd (HKG: 1858, SHA: 688236) has received marketing approval from...
Roche Marks 30 Years in China with Commitment to Boost Investments and Local Manufacturing
Roche (SWX: ROG), the Swiss pharmaceutical giant, has reaffirmed its long-term commitment to the Chinese...